Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


7Seas cancer claims attract FDA attention

This article was originally published in The Tan Sheet

Executive Summary

Supplement claims made by 7Seas LLC on Web sites such as and elicit an April 5 warning letter from FDA's Florida District office. The letter to Norman Hem of the Hialeah, Fla.-based firm alleges that products, including Jade Windscreen, Apricot Seeds and Miracle Mineral Supplement, make disease claims causing them to be unapproved drugs. According to the agency, 7Seas' claims include, "The most powerful, PROVEN cancer treatment and prevention products EVER known to humankind" and "MMS is the answer to ... malaria, hepatitis A, B and C, colds, herpes, TB, most cancer, flu, pneumonia, as well as many other illnesses and diseases." The firm had 15 days to respond to FDA

You may also be interested in...

FDA warns of MMS dangers

FDA warns consumers that Miracle Mineral Solution, also marketed as MMS, produces an industrial bleach when used as directed and can cause serious harm. Several reported health injuries related to the product include "severe nausea, vomiting and life-threatening low blood pressure from dehydration," the agency says in a July 30 alert. MMS, which Hialeah, Fla.-based 7Seas promoted as treating multiple diseases including HIV, hepatitis, H1N1, cancer, the common cold and acne, is sold online by multiple independent distributors. Instructions on product labels direct users to mix the 28 percent sodium chlorite solution with an acidic liquid such as citrus juice, a mixture that produces chlorine dioxide, a potent bleach used to strip textiles. FDA continues to investigate and may pursue civil or criminal enforcement action. FDA sent 7Seas a warning letter in April (1"The Tan Sheet" April 26, 2010)

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

QUOTED. 10 December 2019. Viral Shah.

The global insulin pump market is expected to see significant growth, reaching $5.1bn by 2023. A new Market Intel story looks at the competitive landscape of the three leading companies in this market, Medtronic, Insulet and Tandem Diabetes Care, which are all expected to launch new products in 2020. See what Viral Shah, an assistant professor of medicine and pediatrics at the University of Colorado, said about the diabetes market here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts